Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings

John A. Moss, Marc M. Baum, Amanda M. Malone, Sean Kennedy, Etana Kopin, Cali Nguyen, Josh Gilman, Irina Butkyavichene, Robyn A. Willis, Kathleen Vincent, Massoud Motamedi, Thomas J. Smith

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

OBJECTIVES: To compare the distribution of tenofovir in sheep vaginal lumen, tissue, and plasma following topical delivery of the antiretroviral drug from intravaginal rings, either as tenofovir or the disoproxil fumarate prodrug. DESIGN: Comparative pharmacokinetic study in sheep. METHOD: Intravaginal rings formulated to achieve equivalent release rates of tenofovir and its disoproxil fumarate prodrug were evaluated for 28 days in sheep, with four animals in each group. Drug concentrations were measured by high-performance liquid chromatography-mass spectrometry. RESULTS: Tenofovir levels in cervicovaginal lavage were indistinguishable (P > 0.30) in both groups, but tissue levels in animals receiving the prodrug were 86-fold higher than those receiving tenofovir, and approximately 50 times higher than the level shown to be protective of HIV infection in the CAPRISA 004 trial. CONCLUSION: This is the first study to compare the pharmacokinetics of tenofovir and its disoproxil fumarate prodrug administered topically to the vaginal tract. These in-vivo data show that the prodrug leads to significantly higher drug tissue levels than tenofovir, a finding that may have important implications for the development of preexposure prophylaxis strategies based on topical delivery of antivirals to the female genital tract.

Original languageEnglish (US)
Pages (from-to)707-710
Number of pages4
JournalAIDS
Volume26
Issue number6
DOIs
StatePublished - Mar 27 2012

Fingerprint

Tenofovir
Prodrugs
Pharmacokinetics
Sheep
Pharmaceutical Preparations
Therapeutic Irrigation
HIV Infections
Antiviral Agents
Mass Spectrometry

Keywords

  • intravaginal ring
  • preexposure prophylaxis
  • sheep
  • tenofovir
  • tenofovir disoproxil fumarate
  • topical delivery

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Moss, J. A., Baum, M. M., Malone, A. M., Kennedy, S., Kopin, E., Nguyen, C., ... Smith, T. J. (2012). Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS, 26(6), 707-710. https://doi.org/10.1097/QAD.0b013e3283509abb

Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. / Moss, John A.; Baum, Marc M.; Malone, Amanda M.; Kennedy, Sean; Kopin, Etana; Nguyen, Cali; Gilman, Josh; Butkyavichene, Irina; Willis, Robyn A.; Vincent, Kathleen; Motamedi, Massoud; Smith, Thomas J.

In: AIDS, Vol. 26, No. 6, 27.03.2012, p. 707-710.

Research output: Contribution to journalArticle

Moss, JA, Baum, MM, Malone, AM, Kennedy, S, Kopin, E, Nguyen, C, Gilman, J, Butkyavichene, I, Willis, RA, Vincent, K, Motamedi, M & Smith, TJ 2012, 'Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings', AIDS, vol. 26, no. 6, pp. 707-710. https://doi.org/10.1097/QAD.0b013e3283509abb
Moss JA, Baum MM, Malone AM, Kennedy S, Kopin E, Nguyen C et al. Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. AIDS. 2012 Mar 27;26(6):707-710. https://doi.org/10.1097/QAD.0b013e3283509abb
Moss, John A. ; Baum, Marc M. ; Malone, Amanda M. ; Kennedy, Sean ; Kopin, Etana ; Nguyen, Cali ; Gilman, Josh ; Butkyavichene, Irina ; Willis, Robyn A. ; Vincent, Kathleen ; Motamedi, Massoud ; Smith, Thomas J. / Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings. In: AIDS. 2012 ; Vol. 26, No. 6. pp. 707-710.
@article{79fb88b2095d4339a096f3f7402a0645,
title = "Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings",
abstract = "OBJECTIVES: To compare the distribution of tenofovir in sheep vaginal lumen, tissue, and plasma following topical delivery of the antiretroviral drug from intravaginal rings, either as tenofovir or the disoproxil fumarate prodrug. DESIGN: Comparative pharmacokinetic study in sheep. METHOD: Intravaginal rings formulated to achieve equivalent release rates of tenofovir and its disoproxil fumarate prodrug were evaluated for 28 days in sheep, with four animals in each group. Drug concentrations were measured by high-performance liquid chromatography-mass spectrometry. RESULTS: Tenofovir levels in cervicovaginal lavage were indistinguishable (P > 0.30) in both groups, but tissue levels in animals receiving the prodrug were 86-fold higher than those receiving tenofovir, and approximately 50 times higher than the level shown to be protective of HIV infection in the CAPRISA 004 trial. CONCLUSION: This is the first study to compare the pharmacokinetics of tenofovir and its disoproxil fumarate prodrug administered topically to the vaginal tract. These in-vivo data show that the prodrug leads to significantly higher drug tissue levels than tenofovir, a finding that may have important implications for the development of preexposure prophylaxis strategies based on topical delivery of antivirals to the female genital tract.",
keywords = "intravaginal ring, preexposure prophylaxis, sheep, tenofovir, tenofovir disoproxil fumarate, topical delivery",
author = "Moss, {John A.} and Baum, {Marc M.} and Malone, {Amanda M.} and Sean Kennedy and Etana Kopin and Cali Nguyen and Josh Gilman and Irina Butkyavichene and Willis, {Robyn A.} and Kathleen Vincent and Massoud Motamedi and Smith, {Thomas J.}",
year = "2012",
month = "3",
day = "27",
doi = "10.1097/QAD.0b013e3283509abb",
language = "English (US)",
volume = "26",
pages = "707--710",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Tenofovir and tenofovir disoproxil fumarate pharmacokinetics from intravaginal rings

AU - Moss, John A.

AU - Baum, Marc M.

AU - Malone, Amanda M.

AU - Kennedy, Sean

AU - Kopin, Etana

AU - Nguyen, Cali

AU - Gilman, Josh

AU - Butkyavichene, Irina

AU - Willis, Robyn A.

AU - Vincent, Kathleen

AU - Motamedi, Massoud

AU - Smith, Thomas J.

PY - 2012/3/27

Y1 - 2012/3/27

N2 - OBJECTIVES: To compare the distribution of tenofovir in sheep vaginal lumen, tissue, and plasma following topical delivery of the antiretroviral drug from intravaginal rings, either as tenofovir or the disoproxil fumarate prodrug. DESIGN: Comparative pharmacokinetic study in sheep. METHOD: Intravaginal rings formulated to achieve equivalent release rates of tenofovir and its disoproxil fumarate prodrug were evaluated for 28 days in sheep, with four animals in each group. Drug concentrations were measured by high-performance liquid chromatography-mass spectrometry. RESULTS: Tenofovir levels in cervicovaginal lavage were indistinguishable (P > 0.30) in both groups, but tissue levels in animals receiving the prodrug were 86-fold higher than those receiving tenofovir, and approximately 50 times higher than the level shown to be protective of HIV infection in the CAPRISA 004 trial. CONCLUSION: This is the first study to compare the pharmacokinetics of tenofovir and its disoproxil fumarate prodrug administered topically to the vaginal tract. These in-vivo data show that the prodrug leads to significantly higher drug tissue levels than tenofovir, a finding that may have important implications for the development of preexposure prophylaxis strategies based on topical delivery of antivirals to the female genital tract.

AB - OBJECTIVES: To compare the distribution of tenofovir in sheep vaginal lumen, tissue, and plasma following topical delivery of the antiretroviral drug from intravaginal rings, either as tenofovir or the disoproxil fumarate prodrug. DESIGN: Comparative pharmacokinetic study in sheep. METHOD: Intravaginal rings formulated to achieve equivalent release rates of tenofovir and its disoproxil fumarate prodrug were evaluated for 28 days in sheep, with four animals in each group. Drug concentrations were measured by high-performance liquid chromatography-mass spectrometry. RESULTS: Tenofovir levels in cervicovaginal lavage were indistinguishable (P > 0.30) in both groups, but tissue levels in animals receiving the prodrug were 86-fold higher than those receiving tenofovir, and approximately 50 times higher than the level shown to be protective of HIV infection in the CAPRISA 004 trial. CONCLUSION: This is the first study to compare the pharmacokinetics of tenofovir and its disoproxil fumarate prodrug administered topically to the vaginal tract. These in-vivo data show that the prodrug leads to significantly higher drug tissue levels than tenofovir, a finding that may have important implications for the development of preexposure prophylaxis strategies based on topical delivery of antivirals to the female genital tract.

KW - intravaginal ring

KW - preexposure prophylaxis

KW - sheep

KW - tenofovir

KW - tenofovir disoproxil fumarate

KW - topical delivery

UR - http://www.scopus.com/inward/record.url?scp=84859103724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859103724&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3283509abb

DO - 10.1097/QAD.0b013e3283509abb

M3 - Article

C2 - 22210639

AN - SCOPUS:84859103724

VL - 26

SP - 707

EP - 710

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 6

ER -